Exploring the effect of end-binding proteins and microtubule targeting chemotherapy drugs on microtubule dynamic instability

Publication date: 21 September 2017 Source:Journal of Theoretical Biology, Volume 429 Author(s): Diana White, Stéphane Honoré, Florence Hubert Microtubules (MTs) play a key role in normal cell development and are a primary target for many cancer chemotherapy MT targeting agents (MTAs). As such, understanding MT dynamics in the presence of such agents, as well as other proteins that alter MT dynamics, is extremely important. In general, MTs grow relatively slowly and shorten very fast (almost instantaneously), an event referred to as a catastrophe. These dynamics, referred to as dynamic instability, have been studied in both experimental and theoretical settings. In the presence of MTAs, it is well known that such agents work by suppressing MT dynamics, either by promoting MT polymerization or promoting MT depolymerization. However, recent in vitro experiments show that in the presence of end-binding proteins (EBs), low doses of MTAs can increase MT dynamic instability, rather than suppress it. Here, we develop a novel mathematical model, to describe MT and EB dynamics, something which has not been done in a theoretical setting. Our MT model is based on previous modeling efforts, and consists of a pair of partial differential equations to describe length distributions for growing and shortening MT populations, and an ordinary differential equation (ODE) system to describe the time evolution for concentrations of GTP- and GDP-bound tubulin. A new extension of our...
Source: Journal of Theoretical Biology - Category: Biology Source Type: research

Related Links:

Publication date: Available online 16 July 2019Source: Seminars in Cancer BiologyAuthor(s): Christopher J. Pelham, Masaki Nagane, Esha MadanAbstractIn many cases, cancers are difficult to eliminate because they develop resistance to a primary chemotherapy or targeted therapy. Tumors grow into diverse cell subpopulations, increasing the ability to resist elimination. The phenomenon of ‘cell competition’ describes our body’s natural surveillance system to optimize tissue fitness by forcing viable but aberrant cells to undergo cell death. Cell competition is not simply comparison of cell division potential. ...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 16 July 2019Source: CytotherapyAuthor(s): Keri Toner, Hema Dave, Catherine BollardAbstractT-cell lymphomas represent a subpopulation of non-Hodgkin lymphomas with poor outcomes when treated with conventional chemotherapy. A variety of novel agents have been introduced as new treatment strategies either as first-line treatment or in conjunction with chemotherapy. Immunotherapy has been demonstrated to be a promising area for new therapeutics, including monoclonal antibodies and adoptive cellular therapeutics. T-cell therapeutics have been shown to have significant success in the treatment ...
Source: Cytotherapy - Category: Cytology Source Type: research
Authors: Gallo M, De Luca A, Frezzetti D, Passaro V, Maiello MR, Normanno N Abstract Introduction: Circulating tumor cell (CTC) counts represent an attractive strategy for monitoring response to therapy in patients with advanced non-small cell lung cancer (NSCLC). Changes in the CTCs number during the treatment have been proposed as a predictive biomarker of response to both chemotherapy and targeted therapies. Profiling of CTCs might also allow the assessment of the dynamics of predictive biomarkers such as EGFR, ALK, ROS1, and PD-L1, and provide relevant information in patients progressing on treatment with targe...
Source: Expert Review of Molecular Diagnostics - Category: Laboratory Medicine Tags: Expert Rev Mol Diagn Source Type: research
CONCLUSIONS: Adjuvant trastuzumab has substantially improved the survival of patients with HER2+ eBC, contributing over 41,000 LYG to Spanish society (over 36,000 DFLYG) in a cost-effective manner. However, the sum of LYG with trastuzumab is still far from the LY estimated for the general population, supporting the need of further advances in HER2+ eBC. PMID: 31303965 [PubMed]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Prophylactic radiotherapy — once offered routinely after invasive procedures for pleural mesothelioma — is an unnecessary treatment for patients, according to the most recent study from the United Kingdom. Results from a large, multicenter clinical trial have shown the treatment — used regularly for almost two decades — does little to prevent chest-wall metastasis that can occur with mesothelioma cancer. “This should be helpful for patients to know if their oncologist is offering something they don’t really need,” clinical oncologist Dr. Neil Bayman, associate medical director at t...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
The post All Ears: Seeds of Breakthrough on Chemo Side Effect appeared first on Johns Hopkins Nursing Magazine.
Source: Nursing Blogs at Johns Hopkins University - Category: Nursing Authors: Tags: Cells to Society acupressure auricular point pressure cancer chemotherapy ear neuropathy pain research seeds side effect vaccaria Source Type: blogs
Conditions:   Microbial Colonization;   Colorectal Cancer Interventions:   Drug: Weileshu;   Drug: Chemotherapy Sponsor:   Zhejiang University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Solid Tumor;   Colorectal Cancer;   Pancreatic Cancer Interventions:   Combination Product: PS101 and Ultra Sound for escalation;   Combination Product: PS101 and Ultra Sound for expansion Sponsor:   Phoenix Solutions Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Gastroesophageal Adenocarcinoma Intervention:   Drug: Nivolumab 240 MG Sponsor:   Weill Medical College of Cornell University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Breast Cancer;   Invasive Ductal Breast Carcinoma;   Invasive Lobular Breast Carcinoma Intervention:   Diagnostic Test: Radiomic, pathomic, and clinical markers Sponsor:   Sunnybrook Health Sciences Centre Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Biology | Cancer | Cancer & Oncology | Chemotherapy | Medical Training Application Service